S1332 Decreased 90-Day Mortality Seen With Resumption of Anticoagulation and Performance of Endoscopic Procedures in Patients Hospitalized With a GI Bleed

Introduction: The evidence supporting post-endoscopic management of anticoagulation after bleeding is lacking consensus. Many studies favor resumption of agents to mitigate thrombotic risks; however, timing of resumption is also debatable. Methods: Non-interventional prospective study of all patients in our hospital who were admitted for GI bleeding while on anticoagulation in 2022. The primary outcomes were GI bleeding events, thrombotic events and mortality events within 90 days. We ran a logistic regression analysis to assess correlation between resumption of anticoagulation and primary outcomes. We ran a Mantel-Haenszel analysis between primary outcomes, various bleeding scores to determine a safe timing of resumption in our patient population. Results: 140 patients met our inclusion criteria. Resumption of anticoagulation was significantly associated with decrease in mortality events (P-value 0.001, CI 95% (-0.4 - -0.174)) while there was no association with bleeding or thrombotic events. Performing an endoscopic evaluation was associated with decrease in mortality events (P value 0.025, CI 95% -0.282 - -0.019) and no association with bleeding or thrombotic events. As for timing, there was no significant difference in mortality, bleeding or thrombotic events between days of anticoagulation restart. We assessed timing of anticoagulation resumption based on CHADsVASc, HAS-BLED, Oakland, Glascow Blatchford score. We found these scores did not predict adverse events except a high HAS-BLED score predicted bleeding if resumption was on day 0 of admission. Conclusion: Resumption of anticoagulation seems to be safe and should be prompt once bleeding is addressed. Performance of endoscopic procedures was associated with decreased mortality even in high-risk patients. Decision and safety of anticoagulation seem to be more dependent on the overall status of the patients after their bleeding events are addressed rather than how it was addressed or how they presented.

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001132788.14427.95
Primary Topic
Gastrointestinal Bleeding Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S1332 Decreased 90-Day Mortality Seen With Resumption of Anticoagulation and Performance of Endoscopic Procedures in Patients Hospitalized With a GI Bleed

The American Journal of Gastroenterology
Gastrointestinal Bleeding Diagnosis and Treatment
article

S1332 Decreased 90-Day Mortality Seen With Resumption of Anticoagulation and Performance of Endoscopic Procedures in Patients Hospitalized With a GI Bleed

article en

Abstract

Introduction: The evidence supporting post-endoscopic management of anticoagulation after bleeding is lacking consensus. Many studies favor resumption of agents to mitigate thrombotic risks; however, timing of resumption is also debatable. Methods: Non-interventional prospective study of all patients in our hospital who were admitted for GI bleeding while on anticoagulation in 2022. The primary outcomes were GI bleeding events, thrombotic events and mortality events within 90 days. We ran a logistic regression analysis to assess correlation between resumption of anticoagulation and primary outcomes. We ran a Mantel-Haenszel analysis between primary outcomes, various bleeding scores to determine a safe timing of resumption in our patient population. Results: 140 patients met our inclusion criteria. Resumption of anticoagulation was significantly associated with decrease in mortality events (P-value 0.001, CI 95% (-0.4 - -0.174)) while there was no association with bleeding or thrombotic events. Performing an endoscopic evaluation was associated with decrease in mortality events (P value 0.025, CI 95% -0.282 - -0.019) and no association with bleeding or thrombotic events. As for timing, there was no significant difference in mortality, bleeding or thrombotic events between days of anticoagulation restart. We assessed timing of anticoagulation resumption based on CHADsVASc, HAS-BLED, Oakland, Glascow Blatchford score. We found these scores did not predict adverse events except a high HAS-BLED score predicted bleeding if resumption was on day 0 of admission. Conclusion: Resumption of anticoagulation seems to be safe and should be prompt once bleeding is addressed. Performance of endoscopic procedures was associated with decreased mortality even in high-risk patients. Decision and safety of anticoagulation seem to be more dependent on the overall status of the patients after their bleeding events are addressed rather than how it was addressed or how they presented.

The American Journal of GastroenterologyVol. 120(10S2)
Good health and well-being
Openalex Percentile: Top 32%
Gastrointestinal Bleeding Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.